Ocular	ocular	O	O
and	and	O	O
auditory	auditory	O	O
toxicity	toxicity	O	S_disease
in	in	O	O
hemodialyzed	hemodialyzed	O	O
patients	patients	O	O
receiving	receiving	O	O
desferrioxamine	desferrioxamine	S_chemical	O
.	.	O	O

During	during	O	O
an	an	O	O
18-month	18-month	O	O
period	period	O	O
of	of	O	O
study	study	O	O
41	41	O	O
hemodialyzed	hemodialyzed	O	O
patients	patients	O	O
receiving	receiving	O	O
desferrioxamine	desferrioxamine	S_chemical	O
(	(	O	O
10	10	O	O
-	-	O	O
40	40	O	O
mg/kg	mg/kg	O	O
BW/3	bw/3	O	O
times	times	O	O
weekly	weekly	O	O
)	)	O	O
for	for	O	O
the	the	O	O
first	first	O	O
time	time	O	O
were	were	O	O
monitored	monitored	O	O
for	for	O	O
detection	detection	O	O
of	of	O	O
audiovisual	audiovisual	O	O
toxicity	toxicity	O	S_disease
.	.	O	O

6	6	O	O
patients	patients	O	O
presented	presented	O	O
clinical	clinical	O	O
symptoms	symptoms	O	O
of	of	O	O
visual	visual	O	O
or	or	O	O
auditory	auditory	O	O
toxicity	toxicity	O	S_disease
.	.	O	O

Moreover	moreover	O	O
,	,	O	O
detailed	detailed	O	O
ophthalmologic	ophthalmologic	O	O
and	and	O	O
audiologic	audiologic	O	O
studies	studies	O	O
disclosed	disclosed	O	O
abnormalities	abnormalities	O	O
in	in	O	O
7	7	O	O
more	more	O	O
asymptomatic	asymptomatic	O	O
patients	patients	O	O
.	.	O	O

Visual	visual	O	O
toxicity	toxicity	O	S_disease
was	was	O	O
of	of	O	O
retinal	retinal	O	O
origin	origin	O	O
and	and	O	O
was	was	O	O
characterized	characterized	O	O
by	by	O	O
a	a	O	O
tritan-type	tritan-type	O	O
dyschromatopsy	dyschromatopsy	O	O
,	,	O	O
sometimes	sometimes	O	O
associated	associated	O	O
with	with	O	O
a	a	O	O
loss	loss	O	O
of	of	O	O
visual	visual	O	O
acuity	acuity	O	O
and	and	O	O
pigmentary	pigmentary	O	O
retinal	retinal	O	O
deposits	deposits	O	O
.	.	O	O

Auditory	auditory	O	O
toxicity	toxicity	O	S_disease
was	was	O	O
characterized	characterized	O	O
by	by	O	O
a	a	O	O
mid-	mid-	O	O
to	to	O	O
high-frequency	high-frequency	O	O
neurosensorial	neurosensorial	O	O
hearing	hearing	O	B_disease
loss	loss	O	I_disease
and	and	O	O
the	the	O	O
lesion	lesion	O	O
was	was	O	O
of	of	O	O
the	the	O	O
cochlear	cochlear	O	O
type	type	O	O
.	.	O	O

Desferrioxamine	desferrioxamine	S_chemical	O
withdrawal	withdrawal	O	O
resulted	resulted	O	O
in	in	O	O
a	a	O	O
complete	complete	O	O
recovery	recovery	O	O
of	of	O	O
visual	visual	O	O
function	function	O	O
in	in	O	O
1	1	O	O
patient	patient	O	O
and	and	O	O
partial	partial	O	O
recovery	recovery	O	O
in	in	O	O
3	3	O	O
,	,	O	O
and	and	O	O
a	a	O	O
complete	complete	O	O
reversal	reversal	O	O
of	of	O	O
hearing	hearing	O	B_disease
loss	loss	O	I_disease
in	in	O	O
3	3	O	O
patients	patients	O	O
and	and	O	O
partial	partial	O	O
recovery	recovery	O	O
in	in	O	O
3	3	O	O
.	.	O	O

This	this	O	O
toxicity	toxicity	O	S_disease
appeared	appeared	O	O
in	in	O	O
patients	patients	O	O
receiving	receiving	O	O
the	the	O	O
higher	higher	O	O
doses	doses	O	O
of	of	O	O
desferrioxamine	desferrioxamine	S_chemical	O
or	or	O	O
coincided	coincided	O	O
with	with	O	O
the	the	O	O
normalization	normalization	O	O
of	of	O	O
ferritin	ferritin	O	O
or	or	O	O
aluminium	aluminium	O	O
serum	serum	O	O
levels	levels	O	O
.	.	O	O

The	the	O	O
data	data	O	O
indicate	indicate	O	O
that	that	O	O
audiovisual	audiovisual	O	O
toxicity	toxicity	O	S_disease
is	is	O	O
not	not	O	O
an	an	O	O
infrequent	infrequent	O	O
complication	complication	O	O
in	in	O	O
hemodialyzed	hemodialyzed	O	O
patients	patients	O	O
receiving	receiving	O	O
desferrioxamine	desferrioxamine	S_chemical	O
.	.	O	O

Periodical	periodical	O	O
audiovisual	audiovisual	O	O
monitoring	monitoring	O	O
should	should	O	O
be	be	O	O
performed	performed	O	O
on	on	O	O
hemodialyzed	hemodialyzed	O	O
patients	patients	O	O
receiving	receiving	O	O
the	the	O	O
drug	drug	O	O
in	in	O	O
order	order	O	O
to	to	O	O
detect	detect	O	O
adverse	adverse	O	O
effects	effects	O	O
as	as	O	O
early	early	O	O
as	as	O	O
possible	possible	O	O
.	.	O	O

